In acute myeloid leukaemia (AML), the oncogenic forms of FLT3, BCR-ABL, and KIT drive PI3K-Rho-ROCK-myosin II activation and in vivo tumour growth (Mali et al., 2011). Here, RHO is linked to acute myeloid leukemia.